Latest News From Lumira Ventures

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose …

Forbius Collaborates with the Icahn School of Medicine at Mount Sinai & the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

MPN-RC sponsored, NIH-supported Phase 1/2 trial in myelofibrosis to commence imminently TGF-beta is a central driver of bone marrow fibrosis in myelofibrosis AVID200 selectively inhibits TGF-beta 1 & 3, the principal fibrotic TGF-beta isoforms, while sparing TGF-beta 2, a positive …

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms Reverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models Jan. 7, 2019 …

Exact Imaging Wins 2019 “Life Science Company of the Year” from Life Science Ontario (LSO)

admin Exact Imaging, Portfolio News, Press Release

Exact Imaging’s Novel ExactVu™ Micro-Ultrasound System is Helping Urologists Worldwide Revolutionize Prostate Cancer Detection TORONTO, Nov. 22, 2018 /PRNewswire/ – Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, proudly announces this it has …